Neurology Central

Alzheimer’s drug receives positive results from Phase II study

Eisai Co., Ltd. (Tokyo, Japan) and Biogen Inc. (MA, USA) have announced positive topline results from a Phase II study with BAN2401 – an anti-amyloid beta protofibril antibody – in subjects with early Alzheimer’s disease (AD).

The study is a placebo-controlled, double-blind, parallel-group, randomized trial that examined 856 individuals with early AD. According to the researchers, the study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in AD Composite Score (ADCOMS), and on reduction of amyloid accumulated in the brain, as measured using amyloid-PET.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.